Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $20.00 by Analysts at Barclays

Sarepta Therapeutics (NASDAQ:SRPT) had its target price lowered by investment analysts at Barclays from $22.00 to $20.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s target price indicates a potential upside of 10.87% from the company’s previous close.

SRPT has been the subject of a number of other reports. Guggenheim lowered their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Wednesday. Royal Bank Of Canada increased their target price on Sarepta Therapeutics from $14.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 8th. Sanford C. Bernstein began coverage on Sarepta Therapeutics in a research note on Tuesday, July 29th. They set a “market perform” rating and a $13.00 target price for the company. Leerink Partnrs cut Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 18th. Finally, Leerink Partners increased their target price on Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a research note on Tuesday, September 9th. Eight research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $33.75.

Sarepta Therapeutics Trading Up 11.4%

Shares of SRPT stock traded up $1.84 on Wednesday, reaching $18.04. The company had a trading volume of 6,179,212 shares, compared to its average volume of 6,324,781. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. The stock has a market cap of $1.76 billion, a PE ratio of -20.72 and a beta of 0.52. The company has a 50-day moving average of $20.32 and a 200-day moving average of $26.28. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The company had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business’s revenue was down 14.5% compared to the same quarter last year. During the same period last year, the company earned $0.62 earnings per share. On average, equities analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently made changes to their positions in the stock. State of Michigan Retirement System boosted its holdings in shares of Sarepta Therapeutics by 1.3% in the 1st quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company’s stock valued at $1,461,000 after buying an additional 300 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of Sarepta Therapeutics by 1.1% in the 1st quarter. Louisiana State Employees Retirement System now owns 26,800 shares of the biotechnology company’s stock valued at $1,710,000 after buying an additional 300 shares during the last quarter. Ancora Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Sarepta Therapeutics by 5.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,387 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 358 shares during the last quarter. Finally, Brooklyn Investment Group boosted its holdings in shares of Sarepta Therapeutics by 450.4% in the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 590 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.